Physician profile
Michael D Hamilton
NPI 1427107366
$2,178.68
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $136 · 2021: $300 · 2022: $388 · 2023: $431 · 2024: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.10 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $465.85 | 2022-2024 | |
| Glaxosmithkline, LLC. | $383.30 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $254.03 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $205.24 | 2020-2024 | Mounjaro, Trulicity |
| Horizon Therapeutics Plc | $100.19 | 2019-2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.80 | 2019-2021 | |
| Amgen INC. | $74.49 | 2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $64.44 | 2022-2023 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceutical Holding Company Ltd. | $55.97 | 2022 | |
| Embecta Corp. | $51.37 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Novartis Pharmaceuticals Corporation | $48.21 | 2022-2023 | |
| Allergan, INC. | $40.58 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $32.77 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.48 | 2021 | |
| Exact Sciences Corporation | $24.43 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $21.30 | 2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $20.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.98 | 2021 | |
| Avanir Pharmaceuticals, INC. | $16.11 | 2019 | |
| Phadia US INC. | $15.68 | 2021 | |
| Pfizer INC. | $13.08 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.